It was an absolute pleasure to talk with Jeffrey Curtis (University of Alabama at Birmingham, Birmingham, AL, USA) to discuss whether patients could maintain rheumatoid arthritis remission on monotherapy after discontinuing either methotrexate or etanercept (Clinical Trial Identifier: NCT02373813).
The abstract entitled ‘Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial’ (ABSTRACT NUMBER: 0939) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What are the challenges facing patients in remission on combination therapy of methotrexate plus etanercept? (0:14)
- What is the rationale for discontinuing one of these medications and continuing with monotherapy? (1:47)
- Could you tell us a little about your study, its findings and the implications for clinical practice? (4:42)
- How can remission be regained if it is lost following withdrawal of methotrexate? (6:35)
Disclosure: Consulting fees and research grants to the university from Amgen
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Rheumatoid Arthritis
Andrea Rubbert-Roth, EULAR 2021: The Phase 3 SELECT-CHOICE Study
It was a pleasure to meet with Prof. Andrea Rubbert-Roth (Kantonsspital St Gallen, St Gallen, Switzerland) to discuss the comparative efficacy of upadacitinib and abatacept in patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. The abstract ‘Clinical responses to upadacitinib or abatacept in patients with rheumatoid arthritis by type of prior biologic disease-modifying […]
Roy Fleischmann, EULAR 2021: The Open-label Extension of the SELECT-COMPARE Study
TouchIMMUNOLOGY were delighted to talk with Professor Roy Fleischmann (The University of Texas Southwestern Medical Center and The Metroplex Clinical Research Center, Dallas, TX, US) around the 3 year results from the open-label extension study of upadacitinib or adalimumab in patients with rheumatoid arthritis. ‘Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with […]
Peter Taylor, EULAR 2021: Coadministration of Filgotinib and Statins in Rheumatoid Arthritis
We were delighted to speak with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) around the safety of statin and filgotinib coadministration in patients with rheumatoid arthritis across the DARWIN and FINCH clinical trials. The abstract ‘CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS‘ (POS0660), was presented at the European […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!